

Jan Geissler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10192546/publications.pdf>

Version: 2024-02-01

33
papers

1,563
citations

516710

16
h-index

477307

29
g-index

34
all docs

34
docs citations

34
times ranked

2670
citing authors

#	ARTICLE	IF	CITATIONS
1	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , The, 2011, 12, 933-980.	10.7	571
2	Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 929-939.	1.6	143
3	Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665.	30.7	125
4	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , the, 2018, 5, e563-e598.	4.6	97
5	Improving Patient Involvement in Medicines Research and Development: A Practical Roadmap. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 612-619.	1.6	69
6	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	3.5	67
7	Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1167-1176.	2.5	67
8	Biobanking from the patient perspective. <i>Research Involvement and Engagement</i> , 2015, 1, 4.	2.9	57
9	Patient Involvement in Health Technology Assessment. , 2017, , .		42
10	Culture and Process Change as a Priority for Patient Engagement in Medicines Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 29-38.	1.6	42
11	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	4.5	36
12	A Catalyst for Change: The European Cancer Patient's Bill of Rights. <i>Oncologist</i> , 2014, 19, 217-224.	3.7	35
13	Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. <i>Leukemia</i> , 2020, 34, 2102-2112.	7.2	34
14	What do stakeholders expect from patient engagement: Are these expectations being met?. <i>Health Expectations</i> , 2018, 21, 1035-1045.	2.6	26
15	Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials. <i>Health Expectations</i> , 2020, 23, 41-51.	2.6	23
16	The European Code of Cancer Practice. <i>Journal of Cancer Policy</i> , 2021, 28, 100282.	1.4	22
17	Integrating cancer patients' perspectives into treatment decisions and treatment evaluation using patient-reported outcomes - a concept paper. <i>European Journal of Cancer Care</i> , 2014, 23, 173-179.	1.5	21
18	EUPATI: Collaboration between patients, academia and industry to champion the informed patient in the research and development of medicines. <i>Journal of Medicines Development Sciences</i> , 2015, 1, 74.	0.1	17

#	ARTICLE	IF	CITATIONS
19	Quality of Life in hematology: European Hematology Association theme of the year ... and years to come. <i>Haematologica</i> , 2013, 98, 2-3.	3.5	16
20	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	4.6	11
21	Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer. <i>Leukemia</i> , 2016, 30, 2396-2397.	7.2	8
22	Survey on the worldwide Chronic Myeloid Leukemia Advocates Network regarding complementary and alternative medicine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1025-1031.	2.5	7
23	Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and Reality. <i>Frontiers in Medicine</i> , 2020, 7, 585722.	2.6	5
24	Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. <i>Trials</i> , 2020, 21, 437.	1.6	5
25	Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib. <i>Blood</i> , 2019, 134, 5910-5910.	1.4	4
26	Asciminib (ABL001) in Combination with Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Long-Term Frontline Imatinib: A Randomized, Open-Label, Multicenter, Phase 2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S222-S223.	0.4	3
27	Factors Predicting Intentional Non-Adherence In Chronic Myeloid Leukemia: A Multivariate Analysis On 2546 Patients By The CML Advocates Network. <i>Blood</i> , 2013, 122, 4023-4023.	1.4	3
28	The EHA Research Roadmap: Malignant Myeloid Diseases. <i>HemaSphere</i> , 2021, 5, e635.	2.7	2
29	Identifying Differences in the Quality of Life of Patients with Acute Leukemia: A Global Survey. <i>Blood</i> , 2019, 134, 4785-4785.	1.4	1
30	Improving outcomes through patient-generated evidence—the next step in patient advocacy. <i>Lancet Haematology</i> , 2022, , .	4.6	1
31	Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools. <i>Value in Health</i> , 2022, 25, 1760-1767.	0.3	1
32	CML Patients' Views on Psychological Support throughout the Treatment-Free Remission Journey. <i>Blood</i> , 2019, 134, 2934-2934.	1.4	0
33	Investigating the Quality of Life of Patients with Acute Leukemia, with a Focus on Age and Patient-Reported Experience. <i>Blood</i> , 2020, 136, 25-26.	1.4	0